News
INVO Bioscience Announces “Get to Know INVOcell” – a Series of Facebook Live Events Supporting Access to Affordable Fertility Treatment
Mark Your Calendars for July 7, 2022, with Dr. Sue Ellen Carpenter of Atlanta-based Bloom Fertility SARASOTA, Fla., July 7, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding...
INVO Signs Distribution Agreement with Onesky Holding Limited for Mainland China
Agreement includes minimum purchase obligations upon product registration and approval SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to...
INVO Bioscience Reports First Quarter 2022 Financial Results
Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla., May 16, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its...
INVO Bioscience to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., May 9, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment...
INVO Celebrates National Infertility Awareness Week at the INVO Center in Atlanta, Georgia
Bloom Fertility, an INVO Center to grant three eligible patients a full IVC treatment cycle SARASOTA, Fla., April 28, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment...
INVO Selects Kansas City as additional INVO Center Location
U.S. Market Expansion Continues as Planned SARASOTA, Fla., April 14, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its...
INVO Bioscience to Participate in the Lytham Partners Spring 2022 Investor Conference
SARASOTA, Fla., April 4, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure...
INVO Bioscience Reports 2021 Financial Results
Company to Host Conference Call Today at 4:30pm ET; Slide Presentation Also Available SARASOTA, Fla., March 31, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to...
INVO Bioscience to Report Fourth Quarter and Fiscal Year 2021 Financial Results on Thursday, March 31, 2022
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced...
INVO Bioscience to Exhibit at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting
SARASOTA, Fla., March 24, 2022 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), developers of the INVOcell®, an advanced fertility treatment technology which is currently available, is exhibiting the INVOcell solution at the 2022 Pacific Coast Reproductive...